Gubra CRO helps drug discovery teams make better preclinical decisions faster. As a specialized preclinical contract research organization, we partner with pharmaceutical and biotech companies to generate robust, translational data from early discovery through preclinical development. Our integrated expertise spans in vivo pharmacology, ex vivo assays, drug profiling, histology, RNAseq, and advanced whole-organ 3D imaging. Our CRO services cover a broad range of disease areas, including obesity, MASH/MASLD, diabetes, kidney disease, CNS disorders, IPF and lung fibrosis, women’s health, and muscle disease. Across these areas, we offer validated disease models, integrated study design, quantitative readouts, and expert interpretation to help partners assess efficacy, pharmacology, biodistribution and mechanism of action.
What differentiates Gubra is the combination of deep biological expertise, high-quality translational models, and advanced analytical technologies under one roof. Our teams are experienced in bridging preclinical and clinical development, helping sponsors design studies that answer the right biological and strategic questions. We also bring strong capabilities in 3D imaging, enabling precise visualization and quantification of drug effects and distribution across the brain and other organs at high resolution.
Gubra’s approach is built around scientific partnership, transparency and data quality. Each study is supported by a dedicated study team, ensuring close communication throughout the process. Our proprietary data platform, GubraView, provides sponsors with transparent access to study data and supports efficient data review, visualization and analysis.
By combining disease biology, validated models, advanced imaging, molecular profiling and rigorous study execution, Gubra helps drug discovery teams move faster and with greater confidence. Our value to the industry lies in generating decision-relevant preclinical data that can reduce uncertainty, strengthen translational understanding and support the progression of promising therapeutic candidates toward the clinic
About Drug Discovery Innovation Programme 2026
The Drug Discovery Innovation Programme, organized by World BI, is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2026 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.